• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi sues Merck over injected insulin

September 19, 2016 By Sarah Faulkner

Sanofi, MerckSanofi Aventis (NYSE:SNY) said today that it filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (NYSE:MRK) over 10 U.S. patents related to its injected insulin device.

The Paris-based company said it is seeking an injunction and damages from Merck for filing a new drug application with the FDA that challenged 10 of Sanofi’s patents covering its Lantus and Lantus SoloStar products.

Sanofi’s insulin glargine injection device is a 3 milliliter cartridge, with 100 units of drug per milliliter.

Sanofi said it filed the lawsuit in the U.S. District Court for Delaware, where Merck has fought patent battles before.

Merck notified Sanofi in August that it was filing an NDA for an insulin glargine injection which challenged Sanofi’s the patents associated. Sanofi filed the suit after unsuccessfully trying to negotiate a copy of the NDA from Merck, Sanofi said.

Sanofi also alleges that Merck’s NDA includes data from studies performed in connection with Sanofi’s device.

The suit comes weeks after the FDA requested more data on Sanofi’s iGlarLixi drug-device combination to treat Type II diabetes, delaying the watchdog’s decision date by 3 months.

Sanofi submitted a new drug application for iGlarLixi in December 2015, spending $245 million for priority review, which the FDA granted in February. An advisory panel recommended approval in May, setting the stage for a decision later this month. The FDA’s request for additional information pushes the decision date back to November 2016.

The delay was a blow to Sanofi’s attempt to get the device to market before a similar device by rival Novo Nordisk (NYSE:NVO) is approved. The FDA is set to deliver a decision on Novo Nordisk’s device, iDeglira/Xultophy, sometime this month.

As of Monday afternoon, Merck has not released an official statement about the suit. Sanofi released a brief statement, acknowledging that it filed the suit.

Sanofi’s stock was trading at $38.87 apiece in mid-morning activity today, up 1.14%. Merck was trading at $62.10 apiece, down 0.29%.

Filed Under: Diabetes, Drug-Device Combinations, Legal News Tagged With: Merck, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS